Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axcella Health Inc.AXLA · Entity 116059 | Director | November 16, 2022 | November 18, 2022 |
| Bausch Health Companies Inc.VRX · Entity 4363 | EVP, Corp Dev & Strategy | December 05, 2016 | December 07, 2016 |
| Evelo Biosciences, Inc.EVLO · Entity 108468 | Director | June 08, 2023 | June 12, 2023 |
| Omega Therapeutics, Inc.OMGA · Entity 83618 | Director | October 02, 2024 | October 04, 2024 |
| Sana Biotechnology, Inc.SANA · Entity 4870 | Director | June 04, 2026 | June 05, 2026 |
| Seres Therapeutics, Inc.MCRB · Entity 7191 | Director | July 08, 2026 | July 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axcella Health Inc.
Report date November 16, 2022 · Filed November 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2032-11-15 | Direct | 40,000 |
Reported balance
After 2022-11-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-11-16 · Grant · Acquired 40,000 · Balance 40,000 F1: This option shall vest and become exercisable in twelve equal quarterly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in twelve equal quarterly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date.
Bausch Health Companies Inc.
Report date December 05, 2016 · Filed December 07, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, no par valueSEC Table I · non-derivative | Direct | 517,683 |
Reported balance
After 2016-12-05 transaction · row 1
1 source rowRow 1 · 2016-12-05 · Tax withholding · Disposed 14,687 · Balance 517,683 F1: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. |
Filing footnotes · ownership attribution and instrument terms
F1: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.
Evelo Biosciences, Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.11 · Expires 2033-06-08 | Direct | 30,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests on the earlier of June 8, 2024, and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of June 8, 2024, and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of the grant.
Omega Therapeutics, Inc.
Report date October 02, 2024 · Filed October 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2034-10-01 | Direct | 50,000 |
Reported balance
After 2024-10-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-10-02 · Grant · Acquired 50,000 · Balance 50,000 F1: The option vests and becomes exercisable in thirty-six substantially equal monthly installments following the date of grant, such that the option shall be fully vested and exercisable on the third anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in thirty-six substantially equal monthly installments following the date of grant, such that the option shall be fully vested and exercisable on the third anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such vesting date.
Sana Biotechnology, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2036-06-03 | Direct | 90,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 90,000 · Balance 90,000 F1: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.
Seres Therapeutics, Inc.
Report date July 08, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.14 · Expires 2036-07-07 | Direct | 6,500 |
Reported balance
After 2026-07-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-08 · Grant · Acquired 6,500 · Balance 6,500 F1: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2026 Filed Jul 10, 2026 20:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001193125-26-300926 · ownership.xml · derivative · entry 1 Rosiello Robert L. · CIK 0001645041 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2036-07-07 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:09 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 7,508 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001193125-26-295064 · ownership.xml · derivative · entry 1 Rosiello Robert L. · CIK 0001645041 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,508 Underlying: Common Stock · 7,508 shares Expires 2036-07-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in four equal quarterly installments occurring on October 1, 2026, January 1, 2027, April 1, 2027, and July 1, 2027, provided that if the issuer's 2027 annual meeting of stockholders occurs before July 1, 2027, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting, in each case, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:41 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001645041-26-000002 · primarydocument.xml · derivative · entry 1 Rosiello Robert L. · CIK 0001645041 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. Read SEC document |
| August 05, 2025 Filed Aug 6, 2025 20:10 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $14.28 | $0.00 |
DisclosureSEC source: 0000950170-25-104016 · ownership.xml · derivative · entry 1 Rosiello Robert L. · CIK 0001645041 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-08-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in four equal quarterly installments occurring on August 5, 2026, August 5, 2027, August 5, 2028, August 5, 2029, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:40 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001562180-25-004647 · primarydocument.xml · derivative · entry 1 Rosiello Robert L. · CIK 0001645041 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The option vests and becomes exercisable in 36 equal monthly installments beginning on July 5, 2025, provided that the reporting person provides continuous service to Sana Biotechnology, Inc. through each such date. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 17:10 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000950170-24-112971 · ownership.xml · derivative · entry 1 Rosiello Robert L. · CIK 0001645041 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-10-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in thirty-six substantially equal monthly installments following the date of grant, such that the option shall be fully vested and exercisable on the third anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 16:03 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.11 | $0.00 |
DisclosureSEC source: 0001694665-23-000082 · wk-form4_1686600177.xml · derivative · entry 1 Rosiello Robert L. · CIK 0001645041 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The option vests on the earlier of June 8, 2024, and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of the grant. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 17:12 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.17 | $0.00 |
DisclosureSEC source: 0000899243-23-011385 · doc4.xml · derivative · entry 1 Rosiello Robert L. · CIK 0001645041 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-04-14 F1 · derivative.exercise_date: The option vests in 36 substantially equal monthly installments following the grant date and has a term of 10 years. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 16:15 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001104659-22-120304 · tm2230943-1_4seq1.xml · derivative · entry 1 Rosiello Robert L. · CIK 0001645041 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-11-15 F1 · derivative.exercise_date: This option shall vest and become exercisable in twelve equal quarterly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 05, 2016 Filed Dec 7, 2016 21:40 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | Tax withholdingCommon Stock, no par value | 14,687 | $18.00 | $264,366.00 |
DisclosureSEC source: 0001645041-16-000003 · primary_doc.xml · nonDerivative · entry 1 Rosiello Robert L. · CIK 0001645041 · EVP, Corp Dev & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517,683 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| November 04, 2016 Filed Nov 8, 2016 21:41 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | Tax withholdingCommon Stock, no par value | 817 | $22.06 | $18,023.02 |
DisclosureSEC source: 0001645041-16-000002 · primary_doc.xml · nonDerivative · entry 1 Rosiello Robert L. · CIK 0001645041 · EVP, Corp Dev & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 532,370 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.